Oriola provides restated financial information for the new reporting segments
Oriola Corporation Stock Exchange Release 15 March 2024 at 9.00 a.m. EET
Oriola provides restated financial information for the new reporting segments
Oriola’s segment reporting changed from one to two reporting segments as of 1 January 2024 to reflect the strategy published on 31 October 2023 and to improve transparency. Oriola has restated the financial information for 2022 and 2023 according to the new reporting segments.
From 1 January 2024 onwards, Oriola’s reporting segments are:
- Distribution segment consisting of pharmaceutical logistics and dose dispensing services.
- Wholesale segment consisting of wholesale of traded goods and over-the-counter (OTC) products, parallel import and special licensed medicines, as well as advisory services.
As announced on 13 October 2023, Oriola is divesting Svensk dos AB and thereby exiting the Swedish dose dispending business. The transaction is subject to approval by the Swedish Competition Authority and is expected, based on currently available information, to be completed in the second quarter of 2024. Oriola presents the restated financial information also excluding the Swedish dose dispensing business.
The restated segment information is presented in the Excel and PDF files attached to this release and can also be found on the company’s website: https://www.oriola.com/investors/reports-and-presentations. The financial information presented in this release has not been audited.
Oriola Corporation
Further information:
Timo Leinonen, CFO, [email protected]
Distribution:
Nasdaq Helsinki Ltd
Key media
